The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
Yohei Horikawa - One of the best experts on this subject based on the ideXlab platform.
-
outcome clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel Estramustine Phosphate and carboplatin for castration resistant prostate cancer
International Journal of Clinical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Takeshi Yuasa, Yohei HorikawaAbstract:Objectives Docetaxel-based chemotherapy is effective in patients with castration-resistant prostate cancer (CRPC). This phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, Estramustine Phosphate, and carboplatin (DEC) in patients with CRPC.
-
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with high-risk locali
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa). Methods Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m^2) with Estramustine Phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed. Results No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease. Conclusion We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.
-
short term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in japanese patients with high risk localiz
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).
Shintaro Narita - One of the best experts on this subject based on the ideXlab platform.
-
neoadjuvant luteinizing hormone releasing hormone agonist plus low dose Estramustine Phosphate improves prostate specific antigen free survival in high risk prostate cancer patients a propensity score matched analysis
International Journal of Clinical Oncology, 2015Co-Authors: Takuya Koie, Takahiro Yoneyama, Shintaro Narita, Norihiko Tsuchiya, Koji Mitsuzuka, Sadafumi Kawamura, Yasuhiro Kaiho, Tatsuo Tochigi, Tomonori Habuchi, Yoichi AraiAbstract:Background The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with a neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low dose Estramustine Phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). In the present study, we used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant LHRH+EMP for high-risk Pca.
-
outcome clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel Estramustine Phosphate and carboplatin for castration resistant prostate cancer
International Journal of Clinical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Takeshi Yuasa, Yohei HorikawaAbstract:Objectives Docetaxel-based chemotherapy is effective in patients with castration-resistant prostate cancer (CRPC). This phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, Estramustine Phosphate, and carboplatin (DEC) in patients with CRPC.
-
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with high-risk locali
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa). Methods Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m^2) with Estramustine Phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed. Results No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease. Conclusion We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.
-
short term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in japanese patients with high risk localiz
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).
Tadaichi Kitamura - One of the best experts on this subject based on the ideXlab platform.
-
single nucleotide polymorphisms in the 17β hydroxysteroid dehydrogenase genes might predict the risk of side effects of Estramustine Phosphate sodium in prostate cancer patients
International Journal of Urology, 2005Co-Authors: Motofumi Suzuki, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Shuji Kameyama, Satoru Muto, Kazuo Hara, Kyoichi Tomita, Tadaichi KitamuraAbstract:Background: Estramustine Phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17β-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. Methods: We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer. The association of SNP and individual EMP side-effects was evaluated. Results: Peripheral edema occurred more frequently in patients with C/C genotype of IMS-JST123219 than in those with C/G genotype (OR: 5.47, 95% CI: 1.27–23.64). Haplotype analysis showed that appetite loss was associated with the G allele of IMS-JST123219 and the T allele of IMS-JST123218 (OR: 9.13, 95% CI: 1.15–72.76). Conclusions: These preliminary data demonstrated that analyses of SNP in the HSD17B genes might predict the occurrence of side-effects from EMP.
-
single nucleotide polymorphisms in the 17beta hydroxysteroid dehydrogenase genes might predict the risk of side effects of Estramustine Phosphate sodium in prostate cancer patients
International Journal of Urology, 2005Co-Authors: Motofumi Suzuki, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Shuji Kameyama, Satoru Muto, Kazuo Hara, Kyoichi Tomita, Tadaichi KitamuraAbstract:Background: Estramustine Phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17β-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. Methods: We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer. The association of SNP and individual EMP side-effects was evaluated. Results: Peripheral edema occurred more frequently in patients with C/C genotype of IMS-JST123219 than in those with C/G genotype (OR: 5.47, 95% CI: 1.27–23.64). Haplotype analysis showed that appetite loss was associated with the G allele of IMS-JST123219 and the T allele of IMS-JST123218 (OR: 9.13, 95% CI: 1.15–72.76). Conclusions: These preliminary data demonstrated that analyses of SNP in the HSD17B genes might predict the occurrence of side-effects from EMP.
Norihiko Tsuchiya - One of the best experts on this subject based on the ideXlab platform.
-
neoadjuvant luteinizing hormone releasing hormone agonist plus low dose Estramustine Phosphate improves prostate specific antigen free survival in high risk prostate cancer patients a propensity score matched analysis
International Journal of Clinical Oncology, 2015Co-Authors: Takuya Koie, Takahiro Yoneyama, Shintaro Narita, Norihiko Tsuchiya, Koji Mitsuzuka, Sadafumi Kawamura, Yasuhiro Kaiho, Tatsuo Tochigi, Tomonori Habuchi, Yoichi AraiAbstract:Background The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with a neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low dose Estramustine Phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). In the present study, we used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant LHRH+EMP for high-risk Pca.
-
outcome clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel Estramustine Phosphate and carboplatin for castration resistant prostate cancer
International Journal of Clinical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Takeshi Yuasa, Yohei HorikawaAbstract:Objectives Docetaxel-based chemotherapy is effective in patients with castration-resistant prostate cancer (CRPC). This phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, Estramustine Phosphate, and carboplatin (DEC) in patients with CRPC.
-
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with high-risk locali
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa). Methods Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m^2) with Estramustine Phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed. Results No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease. Conclusion We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.
-
short term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in japanese patients with high risk localiz
World Journal of Surgical Oncology, 2012Co-Authors: Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei HorikawaAbstract:Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and Estramustine Phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).
Motofumi Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
single nucleotide polymorphisms in the 17beta hydroxysteroid dehydrogenase genes might predict the risk of side effects of Estramustine Phosphate sodium in prostate cancer patients
International Journal of Urology, 2005Co-Authors: Motofumi Suzuki, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Shuji Kameyama, Satoru Muto, Kazuo Hara, Kyoichi Tomita, Tadaichi KitamuraAbstract:Background: Estramustine Phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17β-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. Methods: We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer. The association of SNP and individual EMP side-effects was evaluated. Results: Peripheral edema occurred more frequently in patients with C/C genotype of IMS-JST123219 than in those with C/G genotype (OR: 5.47, 95% CI: 1.27–23.64). Haplotype analysis showed that appetite loss was associated with the G allele of IMS-JST123219 and the T allele of IMS-JST123218 (OR: 9.13, 95% CI: 1.15–72.76). Conclusions: These preliminary data demonstrated that analyses of SNP in the HSD17B genes might predict the occurrence of side-effects from EMP.
-
single nucleotide polymorphisms in the 17β hydroxysteroid dehydrogenase genes might predict the risk of side effects of Estramustine Phosphate sodium in prostate cancer patients
International Journal of Urology, 2005Co-Authors: Motofumi Suzuki, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Shuji Kameyama, Satoru Muto, Kazuo Hara, Kyoichi Tomita, Tadaichi KitamuraAbstract:Background: Estramustine Phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17β-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. Methods: We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer. The association of SNP and individual EMP side-effects was evaluated. Results: Peripheral edema occurred more frequently in patients with C/C genotype of IMS-JST123219 than in those with C/G genotype (OR: 5.47, 95% CI: 1.27–23.64). Haplotype analysis showed that appetite loss was associated with the G allele of IMS-JST123219 and the T allele of IMS-JST123218 (OR: 9.13, 95% CI: 1.15–72.76). Conclusions: These preliminary data demonstrated that analyses of SNP in the HSD17B genes might predict the occurrence of side-effects from EMP.
-
incidence of gastrointestinal toxicity during Estramustine Phosphate therapy for prostate cancer is associated with the single nucleotide polymorphisms in the cytochrome p450 1a1 cyp1a1 gene
2005Co-Authors: Mohammed Rafiqul, Satoru Takahashi, Islam Mamun, Motofumi Suzuki, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Shuji Kameyama, Yoichi M Ito, Takumi TakeuchiAbstract:Summary Gastrointestinal toxicity (GIT) is observed frequently during Estramustine Phosphate (EMP) therapy in prostate cancer patients. This adverse effect often deteriorates the patients’ compliance and quality of life, which results in drug discontinuation. The CYP1A1 gene is polymorphic and involves in the metabolism of EMP. Polymorphisms of the CYP1A1 gene might have a role to modulate the metabolism of EMP and convert patients’ ability to comply with the drug toxicities. We performed genotyping of the CYP1A1 gene to reveal interindividual difference of GIT associated with EMP therapy. The study enrolled 126 patients with untreated advanced prostate cancer. Low-dose of EMP was administered orally. Genotyping of m1, m2 and IVS1-728 polymorphisms of the CYP1A1 gene was